Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

New cystic fibrosis transmembrane conductance regulator medicines (e.g., modulators) have revolutionized CF treatment in the United States and extended the lifespan of patients who qualify for them.

A small group of Australians with the rarest kinds of cystic fibrosis – fewer than 200 people – will, for the first time, ...

Affordable access to life-changing treatment for cystic fibrosis will be expanded to more Australians with a change to the ...

Cystic Fibrosis is a rare autosomal recessive disease that causes sticky mucus to build up in the lungs, affecting numerous ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...